臨床外科66巻11号

2011年10月発行

特集 外科医のための最新癌薬物療法

Ⅰ章 臓器別薬物療法

7．肝癌―②術後補助療法

著者： 和田浩志¹ 永野浩昭¹ 丸橋繁¹ 小林省吾¹ 川本弘一¹ 江口英利¹ 種村匡弘¹ 土岐祐一郎¹ 森正樹¹

所属機関： ¹大阪大学大学院医学系研究科消化器外科学

ページ範囲：P.167 - P.175

文献概要

術後補助療法の適応とレジメン選択

　肝細胞癌に対する外科的切除は，最も局所制御に優れた治療であるが，肉眼的な根治切除術施行後であっても高率に肝内再発をきたす．肝細胞癌の肝内再発形式は，肝内転移再発と慢性肝炎や肝硬変を背景とする多中心性発癌の2つがあり，術後早期の再発は，主に肝内転移再発が占めると考えられている^1）．肝細胞癌の長期成績向上には，この肝内再発を抑制する有効な補助療法の開発が必要である^2）．そこで本稿では，現在までに報告された肝細胞癌に対する術後補助療法として，①補助化学療法，②化学療法以外のその他の治療として，インターフェロン治療，免疫療法，分子標的治療薬などの可能性について概説する．

参考文献

1）Sakon M, et al：Clinical significance of hepatic resection in hepatocellular carcinoma：analysis by disease-free survival curves. Arch Surg 135：1456-1459, 2000

2）武田　裕，他：原発性肝癌に対するadjuvant/neoadjuvant chemotherapy．臨外 63：1715-1723, 2008

3）Poon RT, et al：Locoregional therapies for hepatocellular carcinoma：a critical review from the surgeon's perspective. Ann Surg 235：466-486, 2002

4）永野浩昭，左近賢人，門田守人：消化器癌に対する化学療法　肝癌．癌と化療 30：1895-1900, 2003

5）Llovet JM, et al：Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359：378-390, 2008

6）Izumi R, et al：Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20：295-301, 1994

7）Yamamoto M, et al：Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83：336-340, 1996

8）Kohno H, et al：Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma（HCC）. Hepatogastroenterology 43：1405-1409, 1996

9）Lai EC, et al：Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma：a randomized controlled trial. Arch Surg 133：183-188, 1998

10）Ono T, et al：Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients：metaanalysis of three randomized controlled trials. Cancer 91：2378-2385, 2001

11）Kwok PC, et al：Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol 18：450-455, 2003

12）Shuqun C, et al：Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 51：1445-1447, 2004

13）Tanaka S, et al：A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology 52：862-865, 2005

14）Hasegawa K, et al：Uracil-tegafur as an adjuvant for hepatocellular carcinoma：a randomized trial. Hepatology 44：891-895, 2006

15）Peng BG, et al：Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198：313-318, 2009

16）Xia Y, et al：Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection：a randomized controlled trial. Ann Surg Oncol 17：3137-3144, 2010

17）野田剛広，他：動注化学療法の進歩（肝細胞癌）．癌と化療 33：1221-1225，2006

18）Ikeda K, et al：Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32：228-232, 2000

19）Kubo S, et al：Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89：418-422, 2002

20）Sun HC, et al：Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma：a randomized clinical trial. J Cancer Res Clin Oncol 132：458-465, 2006

21）Mazzaferro V, et al：Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44：1543-1554, 2006

22）Lo CM, et al：A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245：831-842, 2007

23）Nagano H, et al：Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 54：172-179, 2007

24）Rosenberg SA, et al：A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316：889-897, 1987

25）Takayama T, et al：Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma：a randomised trial. Lancet 356：802-807, 2000

26）Hui D, et al：A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41：36-41, 2009

27）Spron MB, Newton DL：Chemoprevention of cancr with retinoids. Fed Proc 38：2528-2534, 1979

28）Muto Y, et al：Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 334：1561-1567, 1996

29）Muto Y, Moriwaki H, Saito A：Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340：1046-1047, 1999

30）Okusaka T, et al：Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma（HCC）recurrence in patients with Child-Pugh grade A（CP-A）and small tumor：A subgroup analysis in a phase Ⅱ/Ⅲ randomized, placebo-controlled trial. American Society of Clinical Oncology Gastrointestinal Cancers Symposium（ASCO-GI）2011；General Poster Session B：#165. J Clin Oncol 29（suppl 4）：abstr165, 2011

31）Wang Z, et al：The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 22：876-882, 1995

32）Otuka M, et al：Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein cells via protein kinase A activation. Hepatology 40：243-251, 2004

33）The San-in Group of Liver Surgery：Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma：a prospective randomized trial. Br J Surg 84：1525-1531, 1997

34）Faivre S, et al：Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma：an open-label, multicentre, phase Ⅱ study. Lancet Oncol 10：794-800, 2009

35）Finn RS, et al：Phase Ⅱ, open label study of brivanib alaninate in patients with hepatocellular carcinoma who failed prior antiangiogenic therapy. American Society of Clinical Oncology Gastrointestinal Cancers Symposium（ASCO-GI）2009, General Poster Session C：#200